Ann Pharmacother 2002 Jun;36(6):1085-9
Marisa Battistella BSc Phm, Internal Medicine Clinical Pharmacist, University Health Network - Pharmacy Department ENG 260, 200 Elizabeth St., Toronto, Ontario M5G 2C4, Canada, FAX 416/340-3685, marisa.battistella@uhn.on.ca
[Medline record in process]
OBJECTIVE: To assess the use of fomepizole in the treatment of ethylene glycol poisoning in the absence of hemodialysis. DATA SOURCES: A MEDLINE search (1966-May 2001) of English-language literature pertaining to the use of fomepizole in ethylene glycol poisoning was performed. Key search terms included fomepizole, ethylene glycol poisoning, and hemodialysis. References cited in those articles were also evaluated. DATA SYNTHESIS: Results from a number of case reports and a prospective trial suggest that fomepizole is a safe and effective antidote in the treatment of ethylene glycol poisoning. CONCLUSIONS: Case reports and 1 prospective trial have shown that, in the absence of both renal dysfunction and significant metabolic acidosis, the use of fomepizole should obviate the need for hemodialysis. However, the decision to add hemodialysis in the treatment of ethylene glycol poisoning based on plasma ethylene glycol concentrations is still debatable. A randomized, controlled trial is needed to determine the exact criteria for adding hemodialysis.
PMID: 12022913, UI: 22017628
Order this document
Lancet 2002 May 11;359(9318):1685
Department of Dermatology and Allergology, Klinikum Augsburg, Stenglinstrasse 2, D-86156, Augsburg, Germany
PMID: 12020547, UI: 22016313
Lancet 2002 Apr 27;359(9316):1527
Publication Types:
PMID: 11988287, UI: 21984385
Med J Aust 2002 Mar 4;176(5):242
PMID: 11999246, UI: 21993889
Med J Aust 2002 Mar 4;176(5):240-1
PMID: 11999244, UI: 21993887
the above reports in Macintosh PC UNIX Text HTML format documents on this page through Loansome Doc